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Abstract The pathophysiological role of the tumour necrosis factor (TNF) systemwas studied in adults (n=37) and
children (n=43) non asthmatic offspring of asthmatic parents with and without bronchial hyperreactivity proved by
methacholine airway challenge test. SerumTNFa and its soluble receptors (sTNF-R1 and R2) were determined by en-
zyme-linkedimmunosorbent assay (ELISA).Significantlyelevated TNFa (adults:mean7SD=5?1870?87 pgml1, children:
5?0871?78) vs. non-hyperreactives (adults: 4?1270?43, Po0?0001, children: 3?7570?68, P=0?0084), sTNF-R1 (adults:
1?4470?31ngml1, children: 1?3070?25 vs. adults: 1?2170?14, P=0?0305, children: 1?1370?11ngml1, P=0?0042) and
sTNF-R2 (adults: 0?8570?40 ngml1, children: 0?7070?46 vs. adults: 0?5670?56 P=0?0084, children: 0?3370?17,
P=0?0048) and decreased sTNF-R1/R2 ratio (adults: mean7SD=0?9670?73, children: 2?8572?06 vs. adults:
4?8273?40, P=0?0272, children: 4?4272?30, P=0?0167) weremeasured in patientswith bronchial hyperreactivity.The
provocation doses of methacholine causing a 20% reduction (PD20) in forced expiratory volume in 1sec (FEV1) were
found to be in a significant negative linear correlationwithTNFa, sTNF-R1and R2 levels in hyperreactive adults andwith
TNFa, sTNF-R2 in hyperreactive children.TNFa correlated significantly with its receptors both in hyperreactive adults
andchildren andwiththebodymassindex (BMI) values of adults.TheTNF systemmaycontribute tothepathophysiology
of bronchial hyperreactivity. Altered shedding of sTNF-R1seems to occur in hyperreactive patients.r 2002 Elsevier Science
Ltd
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Tumour necrosis factor (TNF)a and its soluble receptors
(sTNF-R1 and sTNF-R2) may have an importance in the
pathophysiology of bronchial asthma, as it has been de-
monstrated in animal (1) and human models (2^4). The
cytokine may increase the migration and survival of the
eosinophils (5^7) and in£uence the interaction of cells of
the immune system and the bronchial epithelium (8^13).
Increased serum concentrations of sTNF-R1 and R2 (55
and 75kDa isoforms of soluble tumour necrosis factor)
have been detected in the course of acute asthmatic at-
tack (14). Altered shedding of TNF receptors was de-
tected in auto-in£ammatory syndromes (15). The
recently characterised membrane metalloprotease
ADAM 17 seems to cleave both the receptors and theReceived 27 March 2001and accepted in revised form14 November
2001.
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E-mail: cser@gyer1.sote.humembrane-bound forms of TNFa and b, however the
role of another membrane-bound enzymewas also sug-
gested (16).
The aim of the present study is to evaluate the role of
the TNF system, TNFa, soluble TNF-R1 and R2 in non-
asthmatic relatives of asthmatic patients (adults and chil-
dren) with andwithout bronchial hyperreactivitiy.
METHODS
Patients
Five hundred and twenty-seven childhood asthmatic
adults (67?6% male, 32?4% female), previously treated at
the 1st Department of Paediatrics, Semmelweis Univer-
sity Budapest, were asked to come to the hospital for a
re-examination. 145 adult patients [66?2% male, 33?8%
female, age: 37?6575?65 years (mean7SD)] and their
142 children (56?5% male, 43?5% female, age: 11?38
75?73 years)were includedin the study.The adults were
all older than 28years. According toWHO classi¢cation
of asthma severity the patients represented all the four
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their atopic diseases (rhinitis 43%, conjunctivitis15%, skin
manifestations 12%, drug allergy 11%, food allergy 5%,
gastrointestinal complaints 4%, non allergic 43%). Aller-
gic prick skin tests were carried out in each casewith12
inhalative allergens (Soluprick, ALK).
The data presentedhere arepartof a follow-up exam-
ination.The study was approved by the ethical commit-
tee of SemmelweisUniversity. Allpatients involvedin the
study gave their written informed consent.
According to spirometric measurements, symptom-
free patients with hyperreactive and non-hyperreactive
bronchi were chosen for serum TNFa, sTNF-R1 and
sTNF-R2 determination. The inclusion/exclusion criteria
were to be symptom-free and without any medication
for more than 3years (including inhaled steroid or beta-
agonists).Therewere 37 adults and 43 children examined
(Table 1). Their medical history and physical status were
recorded on questionnaires.
TNFa, sTNF-R1and sTNF-R2 measurements were per-
formed in the serum of all the 37 childhood asthmatic
adults and in the 43 o¡spring.
Determination of bronchial hyperreactivity
Aspeci¢c airway challenge tests were performed by in-
creasing doses of methacholine on patients with no pul-
monary symptoms. Methacholine of 1% (Lofarma,
Milano, Italy) was used in appropriate dilution with dis-
tilledwater. Pari ProvocationsTest vaporising equipment
was used for the airway provocation. Spirometric mea-
surements were performed using Sensor Medics Vmax
apparatus. The patients inhaled vaporised methacholine
(0?125, 0?25, 0?5%). A stepwise provocation by inhalation
was performed (1?25 l+2?5 l+5?0 l+10?0 l=18?75 l). TheTABLE 1. The clinical and spirometric data of the patientswith a
Adults (n=37)
Hyperreactives Non-hyperreac
(n=20) (n=17)
Male 11 9
Female 9 8
Mean age 34 years 33 years
(29^44 years) (29^45 year
BMIkgm2
mean7SD
25?7674?443 25?5075?28
CI 95% 23?68^27?84 22?78^28?2
PD20 FEV1
mean7SD
490?97582?9 1759071212
CI 95% 218?1^763?7 3066^7695patient was allowed to inhale the next concentration of
methacholine if symptom-free, and if the reduction of
FEV1 (forcedexspiratory volume in the ¢rst sec)was less
than 20%.Otherwise, the challenge was ¢nished by the
inhalation of18?75 l of the vaporised 0?5% methacholine
solution. Spirometric parameters including FVC (forced
vital capacity) were registered.Bronchial hyperreactivity
was considered at 20% reduction of FEV1 with metha-
choline challenge.
The doses of provocationwhich caused 20% reduction
(PD20) of FEV1were calculated from the change of spiro-
metric parameters and the amount of methacholine
used. In patients without bronchial hyperreactivity, the-
oretical PD20 values were calculated. The PD20 values
were also compared to the serum concentrations of the
cytokine and its receptors.
Since a substantial amount of TNFa can be produced
by the fat tissue (18), the patients’ body mass indexes
(BMI=body weight kg heightm2) were also calculated.
Measurement of serumTNFa and sTNF-R1
and R2
Fasting venous blood samples were collected for TNFa
and sTNF-R1andR2measurements. Serum sampleswere
centrifuged at1100 rpm at room temperature and stored
at801C.The serum concentration of TNFa, (Sigma Im-
munoChemicals, St Louis,MO,USA), solubleTNF-R1and
R2 (Bender MedSystems, Austria) were determined
using enzyme-linked immunosorbent assay (ELISA) kits
according to themanufacturer’s instruction.The absorp-
tionwasmeasured at 450 nmby an ELISA reader.The in-
tra-assay coe⁄cient of variation was 4?2% for TNFa,
1?89 % for sTNF-R1and1?4% for sTNF-R2; the inter-assayndwithout bronchialhyperreactivity
Allpatients n=80
Children (n=43)
tives Hyperreactives Non-hyperreactives
(n=22) (n=21)
14 14
8 7
14 years 15 years
s) (8^21years) (8^23 years)
6 16?6272?328 18?5372?301
2 15?58^17?65 17?49^19?58
0 265?67212?1 546276981
171?5^359?6 199078934
264 RESPIRATORYMEDICINEcoe⁄cient of variation was 7?0, 8?6 and 2?0%, respec-
tively.
The data forTNFa are expressed as pgml1and those
for sTNF-R1and R2 as ngml1.
Statistical analyses
Statistical analyses and graphical illustration of the re-
sults was carried out using the Prism 3,0 statistical and
graphical program. The Mann^Whitney test was used
for comparison of hyperreactive and non-hyperreactive
groups. Linear correlation was calculated using the
Spearman testbetweenTNFa, sTNF-R1and sTNF-R2 con-
centrations and clinical parameters of patients; Po0?05
was regarded signi¢cant.Hyperreactives Non-hyperreactives
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FIG. 1. SerumTNFa, sTNF-R1 and sTNF-R2 concentrations in adu
Horizontal bars representmeanvalues.RESULTS
The patients were divided into bronchial hyperreactive
andnon-hyperreactive groups according to the decrease
of FEV1values after airway challengewith methacholine.
The clinical data of patients and the PD20 values of spiro-
metric parameters are shown inTable1.
Signi¢cantly elevated TNFa concentrations were
found in patients with bronchial hyperreactivity (adults:
mean7SD=5?1870?87pgml1, children: mean7
SD=5?0871?78pgml1) as compared to the non-hyper-
reactive groups (adults: mean7SD=4?1270?43pgml1,
Po0?0001, children: mean7SD=3?7570?68pgml1,
P=0?0084).These data are shown in Fig.1(a).
SolubleTNF-R1 concentrations were also signi¢cantly
higher both in adults and children with bronchial hyper-Hyperreactives Non-hyperreactives
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lt and child patients with and without bronchial hyperreactivity.
TNFSYSTEMINBRONCHIALHYPERREACTIVITY 265reactivity (adults: mean7SD=1?4470?31ngml1, chil-
dren: mean7SD=1?3070?25ngml1) as compared to
non-hyperreactive patients (adults: mean7
SD=1?2170?14ngml1, P=0?0305, children: mean7
SD=1?1370?11ngml1, P=0?0042) in [Fig.1(b)]. Evaluating
the solubleTNF-R2 concentrations,we also observed sig-
ni¢cantly elevated receptor levels both in adult and chil-
dren bronchial hyperreactive groups (adults: mean7
SD=0?8570?40ngml1 vs. mean7SD=0?567
0?56ngml1 P=0?0084, children: mean7SD=0?707
0?46ngml1vs. mean7SD=0.3370?17ngml1,P=0?0048)
[(Fig.1(c)].
TNFa and its receptors correlated signi¢cantly in all
the adult patients (n=37 TNFa^TNF-R1 r=0?4361,
P=0?0070;TNFa^ sTNF-R2 r=0?3708,P=0?0239). Among
the hyperreactive childrenTNFa and sTNF-R2 correlated
with each other (children: TNFa^TNF-R2 r=0?6209
P=0?0020) (Table 2).
The ratio of solubleTNF receptors R1/R2 was signi¢-
cantly higher in the non-hyperreactive groups compared
to the hyperreactives both in adults and children (hyper-
reactive adults: mean7SD=1?9670?73 compared to
non-hyperreactives: mean7SD=4?8273?40 P=0?0272,
hyperreactive children: mean7SD=2?8572?06, non-hy-
perreactives: mean7SD=4?4272?30 P=0?0167) (Fig. 2).
TNFa levels correlated negatively with the PD20 FEV1
values in both adult and child hyperreactive groupsTABLE 2. Correlationof TNFawithsTNF-R1andsTNF-R2 levels
Adults
Hyperreactives Non-hyperr
TNFa TNFa
sTNF-R1 r 0?4881 0?0492
P 0?0290 0?8513
sTNF-R2 r 0?6461 0?1455
P 0?0021 0?5773
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FIG. 2. SerumsTNF-R1/sTNF-R2 valuesin adult andchildpatientsw
sentmeanvalues.(adults FEV1: r=0?4880, P=0?0291; children FEV1:
r=0?6851 P=0?0004; Table 3). SolubleTNF-R1 concen-
trationswere also found to have signi¢cant negative line-
ar correlationwith the PD 20 doses of FEV1 (r=0?4528,
P=0?0450) in adult patients. Soluble sTNF-R2 levels
showed also a negative linear correlation with the PD20
values of adults (FEV1: r=0?6225 P=0?0034) and also in
children (r=0.4340 P=0.0436) (Table 3).The ratio of the
soluble TNF receptors R1/R2 positively correlated with
that parameter in adults (PD20 FEV1: r=0?5368,
P=0?0147;Table 3).
In adults, TNFa [(Fig. 3(a)] and sTNF-R1 [(Fig. 3(b)]
showed a signi¢cant positive linear correlation with BMI
(r=0?3507, P=0?0334 and r=0?4633, P=0?0039 respec-
tively).This was not observed in children.No correlation
was found between PD20 FEV1^BMI,^TNFa/BMI and ^
sTNF-R1/BMI values of adult hyperreactive patients.
DISCUSSION
Wehave detected signi¢cantly higherTNFa, sTNF-R1and
R2 values in symptom-free adult and children patients
with bronchial hyperresponsiveness. TNFa concentra-
tions negatively correlated with the provocation doses
ofmethacholine in the airway challenge tests.inpatientswithhyperreactive andnon-hyperreactivebronchi
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eactives Hyperreactives Non-hyperreactives
TNFa TNFa
0?2477 0?3672
0?2663 0?1015
0?6209 0?0436
0?0020 0?8510
Hyperreactives Non-hyperreactives
0.0
2.5
5.0
7.5
10.0
P=0.0167
sT
N
F-
R1
/sT
N
F-
R2
Children
ith andwithoutbronchialhyperreactivity.Horizontalbarsrepre-
TABLE 3. Correlation of TNFa, sTNF-R1, sTNF-R2 levels and sTNF-R1/sTNF-R2 ratio with the PD20 values of FEV1 in patients
withhyperreactive bronchi
Adults Children
PD20 FEV1 PD20 FEV1
TNFa r 0?4880 0?6851
P 0?0291 0?0004
STNF-R1 r 0?4528 0?1301
P 0?0450 0?5638
STNF-R2 r 0?6225 0?4340
P 0?0034 0?0436
R1/R2 r 0?5368 0?3829
P 0?0147 0?0786
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FIG. 3. Correlation of serumTNFa (a) and sTNF-R1 (b) valueswith BMIin adult patients.Horizontal bars representmeanvalues.
266 RESPIRATORYMEDICINEThese observations support the role of the activation
of theTNF system in the pathomechanism of bronchial
hyperreactivity, as it has already been observed in pa-
tients with bronchial asthma during acute asthmatic at-
tack (14).
The cellular sources of the elevated cytokine and re-
ceptor levels in hyperreactive patients can be the cells of
the immune and thebroncho-alveolar system.Thehigher
cytokine valuesmay indicate the activated state of these
cells (19^21).
Several polymorphisms of theTNF system (-308 G/A
promoter and lymphotoxin-a geneNcoI polymorphisms)
have been observed to be associated with bronchial
asthma (4). Alterations in theTNF gene promoter may
result in higher production of the cytokine in patients
with bronchial hyperreactivity.
The solubleTNF-R1 and R2 can serve as physiological
competitive antagonists of TNFa. The cytokine can
regulate the shedding of its receptors (16). The cor-
relation between TNFa and its soluble receptors may
re£ect an active counter-regulatory mechanism pro-
tecting against the pro-asthmatic e¡ect of the cytokine.
The lower sTNF-R1/R2 ratio in hyperreactive patients
compared to non-hyperreactive ones may be due to adecreased shedding of sTNF-R1 in patients with
bronchial hyperresponsiveness. The alteration of sTNF-
R1 shedding due to the mutation of the extracellular
part of the receptor as a cause of an immunological dis-
order has already been observed in auto-in£ammatory
syndromes (15).
TNFa and its receptors are also expressed in the adi-
pose cells and elevated TNFa levels have been detected
in patients with obesity (18,22).
A correlation of TNFa and sTNF-R1levels with BMI va-
lues of patients was observed in our adult patients.This
supports the role of the fat tissue as an additional source
of the elevated level of TNFa and sTNF-R1.
In conclusion, the contribution of theTNF system can
be raised in bronchial hyperresponsiveness. Di¡erential
shedding of the solubleTNF receptors may also have a
pathophysiological role in this process.
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